An interventional study of Resting state (Control) and Moderate Intensity Continuous Exercise (MICE) in Colorectal Cancer Stage IV, sponsored by Université de Sherbrooke. Completed at 1 site in Canada. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Supportive care
Aerobic exercise is associated with many benefits in patients with cancer treatments. Among these, the reduction of cancer-related fatigue (CRF) is one of the best demonstrated. Besides, several animal models have shown a marked reduction in tumor growth with aerobic exercise, sometimes by more than 60%. As the level of physical activity is convincingly associated with a reduction in the risk of cancer or recurrences, this suggests that aerobic exercise may represent a central therapeutic approach during treatment, both against CRF and for its potential anti-tumor effect.
Both benefits have been suggested to be based on the immunostimulatory and anti-inflammatory effects of exercise. Indeed, systemic inflammatory activity seems to play a central role in the etiology of CRF during cancer treatments, among other things by stimulating the neuro-inflammatory activity of the central nervous system. Also, regarding the anti-tumor effect of exercise, animal models show that this benefit is partly explained by an increase in the activity of immune cells called natural killers (Natural Killer; NK) in tumor tissue and a reduction in the activity of regulatory T cells, the latter having an immunosuppressive effect. However, in humans, the results vary. While some improvement in NK cell activity has been reported in response to aerobic training in breast cancer survivors, others have seen no effect on the immune profile of patients and survivors. On the other hand, some authors report an improvement in the inflammatory profile with training, while others report little or no effect, as well as weak associations with the perception of fatigue.
Although these results seem to discredit the hypothesis of immune and inflammatory regulation of exercise in humans, these studies have all looked at the effect of several weeks of training on the inflammatory and immune profile on an empty stomach and rest. However, several results from the field of exercise immunology convincingly show that the anti-inflammatory effect, as well as the immunostimulating effect of aerobic exercise (including the anti-tumor activity of NK cells) are mainly acute and transient, ie. in the hours following the end of the effort. Furthermore, certain results suggest that in the context of chemotherapy treatments, cyclical treatment by nature, the peaks of fatigue are also acute (i.e. in the days following the treatment) and parallel to peaks of inflammatory activity.
Considering these results, it is therefore plausible to assume that the effect of aerobic exercise on suppressing tumor growth and reducing CRF results rather than the repetition of this acute response at each exercise session. In this case, the prescription of aerobic exercise preceding a session of chemotherapy could potentially represent an interesting therapeutic modality, allowing both the reduction of the CRF associated with this treatment, as well as a better response to the treatment. Besides, as this acute response seems to be highly dependent on the intensity of the effort, high-intensity interval training (HIIT) could be a particularly interesting approach in this context, because it does not require that the high intensity or long-lasting exercise. However, considering the immunosuppressive and pro-inflammatory effects of chemotherapy, the extent of the acute response to exercise may not allow this type of therapeutic use to be considered in this population. To date, no study has attempted to characterize the acute immune and inflammatory response following aerobic exercise in patients currently undergoing chemotherapy treatments.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's enrollment of 19 is below the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Université de Sherbrooke is the lead sponsor of 289 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition (with MRI), then randomly MICE condition and HIIT condition (with MRI).
Other: Resting state (Control) · Other: Moderate Intensity Continuous Exercise (MICE) · Other: High Intensity Interval Exercise (HIIE)
9 cancer patients will be recruited and received the 3 experimental conditions : first the rest condition, then randomly MICE condition and HIIT condition, all without MRI.
Other: Resting state (Control) · Other: Moderate Intensity Continuous Exercise (MICE) · Other: High Intensity Interval Exercise (HIIE)
9 healthy patients will be recruited and received 2 experimental conditions : first the rest condition (with a MRI), then HIIT condition (with MRI).
Other: Resting state (Control) · Other: High Intensity Interval Exercise (HIIE)
Participants were asking to sit on a sofa for 50 minutes.
MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)
Flow cytometry
Time frame: Before the start of the condition (t = 0 minute), at the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes)
Change in the concentration of inflammatory mediators in peripheral blood (chemokines, pro- and anti-inflammatory cytokines)
Luminex immunoassay
Time frame: Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)
Change of hormonal profile (cortisol, corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), adrenaline and noradrenaline)
ELISA Kits and Salivary Cortisol Enzyme ImmunoAssay Kit
Time frame: Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)
Change of Indoleamine-2,3-Dioxygenase activation
Liquid chromatography-mass spectrometry (LCMS)
Time frame: Before the start of the condition (t = 0 minute), At the end of the condition (t = 50 minutes), 1 hour post-condition (t = 110 minutes), 2 hour post-condition (t = 170 minutes)
Cancer-Related Fatigue
Visual Analogue Scale, graduated from 0 (no fatigue) to 10 (extreme fatigue)
Time frame: During 5 days after the day of the condition, 3 times per day
Cerebral integrity - Cerebral blood flow
Functional MRI (pcASL technique)
Time frame: At the end of the condition (t = 50 minutes) within a 30-minute time window
Heart rate variability
Heart rate monitor
Time frame: At the end of the condition, during 10 minutes (t = 50 minutes to t = 60 minutes)
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université de Sherbrooke